January 30 – February 1 2018 |

Boston, MA

 

 

The DNA Damage Response Therapeutics Summit is the first industry-dedicated meeting focused on identifying the next generation of DNA damage response therapeutics, achieving efficacy across a range of contexts, optimizing synthetic lethal screening techniques and exploiting key targets of mechanisms of resistance.

Across 3 content-packed days, the field’s thought leaders from AstraZeneca, Tesaro, Artios, Metabomed, Sierra Oncology and many more will be sharing their insight and lessons learned, collectively enabling the community to:

  • Therapeutically Exploit Synthetic Lethal Interactions for Targeted Cancer Therapy
  • Optimize the Discovery, Clinical Development & Commercialization of Novel Cancer Therapies Based on the Genetic Concept of Synthetic Lethality
  • Leverage Advances in DNA Sequencing and CRISPR-Based Target Discovery to Generate Breakthrough Medicines

Join the foremost industry experts from a diverse range of companies to advance the research and development of drugs targeting novel synthetic lethal pairs.

Download the Full Event Guide here.

Testimonials from our Past Events in the Cell and Viral Immunotherapy Space:

“Overall an excellent program with topical presentations and great opportunities to network with leaders in the field. The fact that it was a very focused meeting with high level people made such interactions possible and made it hugely valuable.”

Virttu Biologics


This Summit is for:

  • Biotech
  • Large Pharma
  • Academics Looking to Network with Industry
  • CRISPR & RNA Screening Companies
  • CROs
  • Model Developers
 Brochure
Photo 4
Media Partner